Tag Archives: Phase III

Ever Bullish, Al Mann Says Afrezza is Coming in Mid-April

Post Exubera, inhaled insulin has been an uphill struggle with regulators. Alfred Mann and MannKind are nonetheless determined to push Afrezza, an ”ultra” rapid-acting mealtime insulin, over the regulatory peak and into the market. Will they succeed, or is MannKind doomed to play Sisyphus on mount FDA? It would be in large part due to […]
Posted in FDA, People, pricing, R&D, Regulatory, Safety, Strategy, Technology | Also tagged , , , , , , | 3 Comments

With Cannabis, Science Trumps Culture, Says GW Pharma CEO

Already approved in 22 countries, GW Pharma’s Sativex product, if approved by FDA, would become the first prescription drug derived from raw cannabis to enter the US market. In the last several years, the US – a place where marijuana still has a decidedly bad reputation, and a prosecutorial history tinged with socioeconomic bias, if […]
Posted in Europe, FDA, Global, Legal, People, R&D, Regulatory, Strategy, Technology | Also tagged , , , , , , , | 2 Comments

Merck Shows Off Bevy of New Drugs

Image by Chemical Heritage Foundation via Flickr While Merck’s net profits might be a little low in the wake of the Schering-Plough merger, it’s pipeline—and future sales—are far from bleak. According to a new report from analyst firm Deutsche Bank, Merck has no less than 18 drugs in Phase III development, with three slated for […]
Posted in R&D, Strategy | Also tagged , , , , , | Leave a comment
  • Categories

  • Meta